维生素C、氢化可的松与硫胺素联合对比单用氢化可的松对脓毒性休克患者无血管加压药支持生存时间的影响:VITAMINS随机临床试验
这项多中心开放标签随机临床试验纳入216例脓毒性休克患者,比较静脉维生素C、氢化可的松与硫胺素联合方案与单用氢化可的松。
要点
- 联合方案未显著改善脓毒性休克患者7天内无血管加压药支持的生存时间。
- 90天死亡率联合组28.6%对比单用组24.5%,无统计学显著差异。
- 10项预设次要结局中9项无显著差异,未报告严重不良事件。
核心结论
- 在脓毒性休克患者中,静脉维生素C、氢化可的松与硫胺素联合治疗对比单用氢化可的松,未显著改善7天内无血管加压药支持的生存时间。
- 联合方案并未较单用氢化可的松更快缓解脓毒性休克。
研究设计与样本
- 多中心、开放标签、随机临床试验,在澳大利亚、新西兰和巴西的10个重症监护病房开展。
- 共招募216例符合Sepsis-3脓毒性休克定义的患者,随机分为干预组109例和对照组107例。
- 干预组接受静脉维生素C 1.5 g每6小时、氢化可的松50 mg每6小时、硫胺素200 mg每12小时;对照组单用静脉氢化可的松50 mg每6小时,直至休克缓解或最长10天。
- 主要结局为至第7天无血管加压药支持的生存时间;预设10项次要结局,包括90天死亡率。
- 211例患者提供知情同意并完成主要结局测量(平均年龄61.7岁,SD 15.0;男性133例,63%)。
主要发现
- 至第7天无血管加压药支持的生存时间:干预组122.1小时(IQR 76.3-145.4),对照组124.6小时(IQR 82.1-147.0)。
- 10项预设次要结局中9项无统计学显著差异。
- 90天死亡率:干预组30/105(28.6%),对照组25/102(24.5%),风险比1.18(95%CI 0.69-2.00)。
- 未报告严重不良事件。
临床怎么用
- 对于脓毒性休克患者,不支持常规使用维生素C、氢化可的松与硫胺素联合方案以期加速休克缓解。
- 单用氢化可的松仍是该试验条件下可考虑的糖皮质激素使用方式。
局限性
- 开放标签设计可能引入偏倚。
- 样本量216例,事件数有限,90天死亡率估计的置信区间较宽。
- 研究仅在澳大利亚、新西兰和巴西的10个ICU开展,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It is unclear whether vitamin C, hydrocortisone, and thiamine are more effective than hydrocortisone alone in expediting resolution of septic shock. OBJECTIVE: To determine whether the combination of vitamin C, hydrocortisone, and thiamine, compared with hydrocortisone alone, improves the duration of time alive and free of vasopressor administration in patients with septic shock. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, open-label, randomized clinical trial conducted in 10 intensive care units in Australia, New Zealand, and Brazil that recruited 216 patients fulfilling the Sepsis-3 definition of septic shock. The first patient was enrolled on May 8, 2018, and the last on July 9, 2019. The final date of follow-up was October 6, 2019. INTERVENTIONS: Patients were randomized to the intervention group (n = 109), consisting of intravenous vitamin C (1.5 g every 6 hours), hydrocortisone (50 mg every 6 hours), and thiamine (200 mg every 12 hours), or to the control group (n = 107), consisting of intravenous hydrocortisone (50 mg every 6 hours) alone until shock resolution or up to 10 days. MAIN OUTCOMES AND MEASURES: The primary trial outcome was duration of time alive and free of vasopressor administration up to day 7. Ten secondary outcomes were prespecified, including 90-day mortality. RESULTS: Among 216 patients who were randomized, 211 provided consent and completed the primary outcome measurement (mean age, 61.7 years [SD, 15.0]; 133 men [63%]). Time alive and vasopressor free up to day 7 was 122.1 hours (interquartile range [IQR], 76.3-145.4 hours) in the intervention group and 124.6 hours (IQR, 82.1-147.0 hours) in the control group; the median of all paired differences was -0.6 hours (95% CI, -8.3 to 7.2 hours; P = .83). Of 10 prespecified secondary outcomes, 9 showed no statistically significant difference. Ninety-day mortality was 30/105 (28.6%) in the intervention group and 25/102 (24.5%) in the control group (hazard ratio, 1.18; 95% CI, 0.69-2.00). No serious adverse events were reported. CONCLUSIONS AND RELEVANCE: In patients with septic shock, treatment with intravenous vitamin C, hydrocortisone, and thiamine, compared with intravenous hydrocortisone alone, did not significantly improve the duration of time alive and free of vasopressor administration over 7 days. The finding suggests that treatment with intravenous vitamin C, hydrocortisone, and thiamine does not lead to a more rapid resolution of septic shock compared with intravenous hydrocortisone alone. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03333278.
引用
- Fujii T, Luethi N, Young PJ, et al. Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial. JAMA. 2020. PMID: 31950979. doi:10.1001/jama.2019.22176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。